Strahlentherapie und Onkologie

, Volume 194, Issue 4, pp 360–362 | Cite as

Kombination aus perkutaner Strahlentherapie, Brachytherapie und Androgendeprivation gleichwertige Alternative zur radikalen Prostatektomie beim Prostatakarzinom

Literatur kommentiert

Combination of percutaneous radiotherapy, brachytherapy, and androgen deprivation equivalent alternatives to radical prostatectomy for prostate cancer



C. Zamboglou und A. L. Grosu geben an, dass kein Interessenkonflikt besteht.


  1. 1.
    Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G et al (2017) Clinical outcomes for patients with Gleason score 9–10 prostate adenocarcinoma treated with radiotherapy or radical prostatectomy: a multi-institutional comparative analysis. Eur Urol 71:766–773CrossRefPubMedGoogle Scholar
  2. 2.
    Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M et al (2017) Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate Brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98:275–285CrossRefPubMedGoogle Scholar
  3. 3.
    Zelefsky MJ, Eastham JA, Cronin AM, Fuks Z, Zhang Z, Yamada Y et al (2010) Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 28:1508–1513CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Wallis CJD, Saskin R, Choo R, Herschorn S, Kodama RT, Satkunasivam R et al (2016) Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol 70:21–30CrossRefPubMedGoogle Scholar
  5. 5.
    Johnson SB, Lester-Coll NH, Kelly JR, Kann BH, Yu JB, Nath SK (2017) Brachytherapy boost utilization and survival in unfavorable-risk prostate cancer. Eur Urol 72:738–744CrossRefPubMedGoogle Scholar
  6. 6.
    Zelefsky MJ, Reuter VE, Fuks Z, Scardino P, Shippy A (2008) Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 179:1368–1373 (discussion 73)CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Martinez AA, Gonzalez J, Ye H, Ghilezan M, Shetty S, Kernen K et al (2011) Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with Hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 79:363–370CrossRefPubMedGoogle Scholar
  8. 8.
    Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H et al (2017) ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98:286–295CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Radiation Oncology Medical Center and Medical FacultyUniversity of Freiburg, Germany German Cancer Consortium (DKTK) Partner Site FreiburgFreiburgDeutschland

Personalised recommendations